22 January 2021 in IEEE Internet of Things Journal
Blockchain technology is rapidly changing the transaction behavior and efficiency of businesses in recent years. Data privacy and system reliability are critical issues that is highly required to be addressed in Blockchain environments. However, anomaly intrusion poses a significant threat to a Blockchain, and therefore, it is proposed in this article a collaborative clustering-characteristic-based data fusion approach for intrusion detection in a Blockchain-based system, where a mathematical model of data fusion is designed and an AI model is used to train and analyze data clusters in Blockchain networks. The abnormal characteristics in a Blockchain data set are identified, a weighted combination is carried out, and the weighted coefficients among several nodes are obtained after multiple rounds of mutual competition among clustering nodes. When the weighted coefficient and a similarity matching relationship follow a standard pattern, an abnormal intrusion behavior is accurately and collaboratively detected. Experimental results show that the proposed algorithm has high recognition accuracy and promising performance in the real-time detection of attacks in a Blockchain.
20 July 2005 in BMC Cancer
Background: Currently, no satisfactory biomarkers are available to screen for lung cancer. Surface-Enhanced Laser Desorption/ionization Time-of- Flight Mass Spectrometry ProteinChip system (SELDI-TOF-MS) is one of the currently used techniques to identify biomarkers for cancers. The aim of this study is to explore the application of serum SELDI proteomic patterns to distinguish lung cancer patients from healthy individuals. Methods: A total of 208 serum samples, including 158 lung cancer patients and 50 healthy individuals, were randomly divided into a training set (including 11 sera from patients with stages I/II lung cancer, 63 from patients with stages III/IV lung cancer and 20 from healthy controls) and a blinded test set (including 43 sera from patients with stages I/II lung cancer, 41 from patients with stages III/IV lung cancer and 30 from healthy controls). All samples were analyzed by SELDI technology. The spectra were generated on weak cation exchange (WCX2) chips, and protein peaks clustering and classification analyses were made using Ciphergen Biomarker Wizard and Biomarker Pattern software, respectively. We additionally determined Cyfra21-1 and NSE in the 208 serum samples included in this study using an electrochemiluminescent immunoassay. Results: Five protein peaks at 11493, 6429, 8245, 5335 and 2538 Da were automatically chosen as a biomarker pattern in the training set. When the SELDI marker pattern was tested with the blinded test set, it yielded a sensitivity of 86.9%, a specificity of 80.0% and a positive predictive value of 92.4%. The sensitivities provided by Cyfra21-1 and NSE used individually or in combination were significantly lower than that of the SELDI marker pattern (P < 0.005 or 0.05, respectively). Based on the results of the test set, we found that the SELDI marker pattern showed a sensitivity of 91.4% in the detection of non-small cell lung cancers (NSCLC), which was significantly higher than that in the detection of small cell lung cancers (P < 0.05); The pattern also had a sensitivity of 79.1% in the detection of lung cancers in stages I/II. Conclusion: These results suggest that serum SELDI protein profiling can distinguish lung cancer patients, especially NSCLC patients, from normal subjects with relatively high sensitivity and specificity, and the SELDI-TOF-MS is a potential tool for the screening of lung cancer.
30 May 2007 in Cancer Science
The development of metastasis is the leading cause of death and an enormous therapeutic challenge in cases of non‐small cell lung cancer. To better understand the molecular mechanisms underlying the metastasis process and to discover novel potential clinical markers for non‐small cell lung cancer, comparative proteomic analysis of two non‐small cell lung cancer cell lines with different metastatic potentials, the non‐metastatic CL1‐0 and highly metastatic CL1‐5 cell lines, was carried out using two‐dimensional electrophoresis followed by matrix‐assisted laser desorption ionization–time of flight mass spectrometry and tandem mass spectrometry. Thirty‐three differentially expressed proteins were identified unambiguously, among which 16 proteins were significantly upregulated and 17 proteins were downregulated in highly metastatic CL1‐5 cells compared with non‐metastatic CL1‐0 cells. Subsequently, 8 of 33 identified proteins were selected for further validation at the mRNA level using real‐time quantitative polymerase chain reaction, and three identified proteins, S100A11, PGP 9.5 and HSP27, were confirmed by western blotting. The protein S100A11 displaying significant differential expression at both the protein and mRNA levels was further analyzed by immunohistochemical staining in 65 primary non‐small cell lung cancer tissues and 10 matched local positive lymph node specimens to explore its relationship with metastasis. The results indicated that the upregulation of S100A11 expression in non‐small cell lung cancer tissues was significantly associated with higher tumor–node–metastasis stage (P = 0.001) and positive lymph node status (P = 0.011), implying that S100A11 might be an important regulatory molecule in promoting invasion and metastasis of non‐small cell lung cancer. (Cancer Sci 2007; 98: 1265–1274)
1 January 2003 in Disease Markers
Lung cancer is at present the number one cause of cancer death and no biomarker is available to detect early lung cancer in serum samples so far. The objective of this study is to find specific biomarkers for detection of lung cancer using Surface Enhanced Laser Desorption/Ionization (SELDI) technology. In this study, serum samples from 30 lung cancer patients and 51 age‐and sex‐matched healthy were analyzed by SELDI based ProteinChip reader, PBSII‐C. The spectra were generated on WCX2 chips and protein peaks clustering and classification analyses were performed utilizing Biomarker Wizard and Biomarker Patterns software packages, respectively. Three protein peaks were automatically chosen for the system training and the development of a decision classification tree. The constructed model was then used to test an independent set of masked serum samples from 15 lung cancer patients and 31 healthy individuals. The analysis yielded a sensitivity of 93.3%, and a specificity of 96.7%. These results suggest that the serum is a capable resource for detection of specific lung cancer biomarkers. SELDI technique combined with an artificial intelligence classification algorithm can both facilitate the discovery of better biomarkers for lung cancer and provide a useful tool for molecular diagnosis in future.
1 October 2006 in Lung Cancer
23 August 2011 in Molecular and Cellular Biochemistry